Latest Period
Q4 2025
Security Snapshot
CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) Institutional Ownership
CUSIP: 23284F105
13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026
Institutions Reporting
123
Shares (Excl. Options)
144,062,799
Price
$4.26
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.00001 per share
- Symbol
- CTMX on Nasdaq
- Shares outstanding
- 217,291,620
- Price per share
- $4.30
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 144,062,799
- Total reported value
- $613,710,984
- % of total 13F portfolios
- 0%
- Share change
- +5,784,199
- Value change
- +$47,359,677
- Number of holders
- 123
- Price from insider filings
- $4.30
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CTMX - CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 23284F105.
- 123 institutions reported positions in Q4 2025.
- 10 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 123 to 27 between Q4 2025 and Q1 2026.
- Reported value moved from $613,710,984 to $7,491,693.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 123 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 23284F105?
CUSIP 23284F105 identifies CTMX - CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23284F105:
Significant Owners of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +18% | $105,171,344 | +$17,756,285 | 24,688,109 | +20% | FMR LLC | 31 Dec 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 9.4% | +15% | $49,641,185 | +$8,195,110 | 15,561,500 | +20% | Venrock Healthcare Capital Partners III, L.P. | 30 Sep 2025 |
| Longitude Capital Partners V, LLC | 7.3% | $8,192,307 | 11,538,461 | Longitude Capital Partners V, LLC | 13 May 2025 | |||
| Point72 Asset Management, L.P. | 5% | +83% | $51,063,531 | +$31,941,228 | 10,864,581 | +167% | Point72 Asset Management, L.P. | 15 Apr 2026 |
| PERCEPTIVE ADVISORS LLC | 5.9% | $22,458,029 | 9,680,185 | Perceptive Advisors LLC | 14 Aug 2025 | |||
| Kynam Capital Management, LP | 5.3% | $48,685,798 | 8,966,077 | Kynam Capital Management, LP | 31 Dec 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 3.5% | -47% | $17,250,001 | -$17,250,001 | 5,769,231 | -50% | BVF PARTNERS L P/IL | 03 Jul 2025 |
| ORBIMED ADVISORS LLC | 2.1% | -66% | $15,160,295 | -$21,224,155 | 3,525,650 | -58% | OrbiMed Advisors LLC | 31 Dec 2025 |
| Seven Fleet Partners LP | 0.2% | $267,784 | 377,161 | Seven Fleet Partners LP | 13 May 2025 | |||
| Seven Fleet Capital Management LP | 0.02% | $155,985 | 48,898 | Seven Fleet Master Fund LP | 30 Sep 2025 |
As of 31 Dec 2025, 123 institutional investors reported holding 144,062,799 shares of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX). This represents 66% of the company’s total 217,291,620 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 24,688,109 | +60% | 0.01% | $105,171,344 |
| VR ADVISER, LLC | 7.2% | 15,561,500 | 0% | 3.3% | $66,291,990 |
| PERCEPTIVE ADVISORS LLC | 4.5% | 9,680,185 | 0% | 0.76% | $41,237,588 |
| Kynam Capital Management, LP | 4.1% | 8,966,077 | +146% | 2.5% | $38,195,488 |
| VANGUARD GROUP INC | 3.9% | 8,475,584 | -5.3% | 0% | $36,105,988 |
| Commodore Capital LP | 3.5% | 7,692,300 | 0% | 2.2% | $32,769,198 |
| Point72 Asset Management, L.P. | 2.4% | 5,189,538 | +28% | 0.03% | $22,107,432 |
| STATE STREET CORP | 2.4% | 5,140,931 | +697% | 0% | $21,900,366 |
| BAKER BROS. ADVISORS LP | 2% | 4,250,826 | 0% | 0.11% | $18,108,519 |
| ADAR1 Capital Management, LLC | 1.9% | 4,182,769 | +3.4% | 1.3% | $17,818,596 |
| Balyasny Asset Management L.P. | 1.8% | 3,872,202 | -1% | 0.03% | $16,495,581 |
| Financial Engines Advisors L.L.C. | 1.8% | 3,828,717 | +177% | 0.03% | $16,310,334 |
| BlackRock, Inc. | 1.7% | 3,669,393 | +54% | 0% | $15,631,615 |
| ORBIMED ADVISORS LLC | 1.6% | 3,525,650 | -58% | 0.32% | $15,019,269 |
| Ikarian Capital, LLC | 1.5% | 3,172,616 | -5.9% | 1.8% | $13,515,344 |
| Vivo Capital, LLC | 1.3% | 2,884,615 | 0% | 0.79% | $12,288,460 |
| Eversept Partners, LP | 1.2% | 2,507,090 | 0.6% | $10,680,203 | |
| GOLDMAN SACHS GROUP INC | 1.1% | 2,460,944 | +450% | 0% | $10,483,622 |
| Woodline Partners LP | 1.1% | 2,337,005 | 0% | 0.04% | $9,955,641 |
| TWO SIGMA INVESTMENTS, LP | 0.72% | 1,560,755 | +114% | 0.01% | $6,648,816 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.7% | 1,525,666 | -2.8% | 0% | $6,502,652 |
| DIMENSIONAL FUND ADVISORS LP | 0.59% | 1,289,656 | +186% | 0% | $5,492,186 |
| MARSHALL WACE, LLP | 0.53% | 1,156,936 | +4.7% | 0% | $4,928,547 |
| Qube Research & Technologies Ltd | 0.49% | 1,061,128 | +766% | 0.01% | $4,520,405 |
| STEMPOINT CAPITAL LP | 0.48% | 1,036,311 | 0.76% | $4,414,685 |
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, par value $0.00001 per share (CTMX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,594,235 | $7,491,693 | +$1,540,066 | $4.70 | 27 |
| 2025 Q4 | 144,062,799 | $613,710,984 | +$47,359,677 | $4.26 | 123 |
| 2025 Q3 | 137,411,371 | $438,342,190 | +$24,527,196 | $3.19 | 102 |
| 2025 Q2 | 133,305,109 | $302,602,132 | +$213,797,054 | $2.27 | 82 |
| 2025 Q1 | 45,180,958 | $28,723,084 | -$1,507,772 | $0.64 | 63 |
| 2024 Q4 | 46,714,805 | $48,111,898 | -$6,381,441 | $1.03 | 68 |
| 2024 Q3 | 51,193,741 | $60,427,306 | +$480,690 | $1.18 | 69 |
| 2024 Q2 | 50,687,257 | $61,863,474 | +$334,609 | $1.22 | 73 |
| 2024 Q1 | 44,548,308 | $97,118,414 | +$26,024,246 | $2.18 | 85 |
| 2023 Q4 | 32,640,376 | $50,592,909 | +$410,206 | $1.55 | 66 |
| 2023 Q3 | 32,393,313 | $41,785,804 | -$2,418,556 | $1.29 | 61 |
| 2023 Q2 | 34,120,916 | $58,688,106 | -$2,378,087 | $1.72 | 66 |
| 2023 Q1 | 35,594,054 | $53,751,153 | -$933,381 | $1.51 | 74 |
| 2022 Q4 | 35,979,014 | $120,192,376 | -$724,794 | $1.60 | 77 |
| 2022 Q3 | 36,281,610 | $52,604,898 | -$18,986,577 | $1.45 | 76 |
| 2022 Q2 | 45,579,430 | $83,410,352 | -$17,825,825 | $1.83 | 86 |
| 2022 Q1 | 53,661,262 | $143,355,949 | -$1,754,233 | $2.67 | 112 |
| 2021 Q4 | 54,342,875 | $235,299,521 | -$5,313,006 | $4.33 | 106 |
| 2021 Q3 | 53,978,233 | $274,775,521 | -$17,338,127 | $5.09 | 111 |
| 2021 Q2 | 56,688,576 | $358,879,555 | +$4,313,452 | $6.33 | 119 |
| 2021 Q1 | 54,613,642 | $422,156,729 | +$130,257,296 | $7.73 | 123 |
| 2020 Q4 | 37,995,365 | $248,881,255 | +$5,576,359 | $6.55 | 123 |
| 2020 Q3 | 36,841,081 | $245,069,950 | -$11,639,890 | $6.65 | 128 |
| 2020 Q2 | 37,758,348 | $314,514,192 | +$15,532,613 | $8.33 | 133 |
| 2020 Q1 | 36,087,916 | $276,879,388 | +$244,869 | $7.67 | 113 |
| 2019 Q4 | 36,001,618 | $299,160,261 | -$9,333,104 | $8.31 | 119 |
| 2019 Q3 | 35,837,109 | $264,433,175 | -$1,377,891 | $7.38 | 111 |
| 2019 Q2 | 35,647,194 | $399,598,509 | -$8,094,164 | $11.22 | 108 |
| 2019 Q1 | 36,897,584 | $396,629,592 | -$12,805,896 | $10.75 | 110 |
| 2018 Q4 | 37,768,617 | $569,884,178 | -$2,745,916 | $15.10 | 108 |
| 2018 Q3 | 37,780,542 | $697,391,587 | +$95,602,749 | $18.50 | 119 |
| 2018 Q2 | 32,308,752 | $738,633,935 | +$66,042,910 | $22.86 | 139 |
| 2018 Q1 | 28,622,740 | $814,197,912 | +$73,379,749 | $28.45 | 136 |
| 2017 Q4 | 30,146,848 | $636,945,631 | +$56,049,834 | $21.11 | 119 |
| 2017 Q3 | 24,242,512 | $440,733,363 | +$42,038,227 | $18.17 | 97 |
| 2017 Q2 | 22,105,676 | $342,719,825 | +$44,092,931 | $15.50 | 89 |
| 2017 Q1 | 19,204,130 | $331,600,145 | +$58,337,064 | $17.27 | 86 |
| 2016 Q4 | 16,857,707 | $185,279,386 | +$14,954,410 | $10.99 | 68 |
| 2016 Q3 | 19,725,140 | $242,759,481 | +$18,076,577 | $15.68 | 61 |
| 2016 Q2 | 18,845,409 | $149,178,103 | +$16,034,432 | $10.21 | 59 |
| 2016 Q1 | 12,778,869 | $164,816,000 | +$3,379,204 | $12.90 | 47 |
| 2015 Q4 | 12,469,279 | $258,260,359 | +$239,918,359 | $20.87 | 47 |